SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-21-146371
Filing Date
2021-12-03
Accepted
2021-12-03 16:32:11
Documents
13
Period of Report
2021-12-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2134539d1_8k.htm   iXBRL 8-K 27347
2 EXHIBIT 1.1 tm2134539d1_ex1-1.htm EX-1.1 240079
  Complete submission text file 0001104659-21-146371.txt   499736

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA srne-20211203.xsd EX-101.SCH 3061
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE srne-20211203_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE srne-20211203_pre.xml EX-101.PRE 22383
6 EXTRACTED XBRL INSTANCE DOCUMENT tm2134539d1_8k_htm.xml XML 3484
Mailing Address 4955 DIRECTORS PLACE SAN DIEGO CA 92121
Business Address 4955 DIRECTORS PLACE SAN DIEGO CA 92121 858-203-4100
Sorrento Therapeutics, Inc. (Filer) CIK: 0000850261 (see all company filings)

IRS No.: 330344842 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36150 | Film No.: 211470475
SIC: 2836 Biological Products, (No Diagnostic Substances)